CO2018007008A2 - "procesos mejorados para la preparación de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo" - Google Patents

"procesos mejorados para la preparación de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo"

Info

Publication number
CO2018007008A2
CO2018007008A2 CONC2018/0007008A CO2018007008A CO2018007008A2 CO 2018007008 A2 CO2018007008 A2 CO 2018007008A2 CO 2018007008 A CO2018007008 A CO 2018007008A CO 2018007008 A2 CO2018007008 A2 CO 2018007008A2
Authority
CO
Colombia
Prior art keywords
azd9291
salt
osimertinib
preparation
improved processes
Prior art date
Application number
CONC2018/0007008A
Other languages
English (en)
Spanish (es)
Inventor
Alistair John Boyd
Alexander Telford
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57984913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2018007008(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO2018007008A2 publication Critical patent/CO2018007008A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CONC2018/0007008A 2016-02-01 2018-07-04 "procesos mejorados para la preparación de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo" CO2018007008A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662289390P 2016-02-01 2016-02-01
PCT/EP2017/052050 WO2017134051A1 (en) 2016-02-01 2017-01-31 Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and "azd9291 aniline" or a salt thereof

Publications (1)

Publication Number Publication Date
CO2018007008A2 true CO2018007008A2 (es) 2018-07-19

Family

ID=57984913

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0007008A CO2018007008A2 (es) 2016-02-01 2018-07-04 "procesos mejorados para la preparación de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo"

Country Status (18)

Country Link
US (1) US11180477B2 (enExample)
EP (1) EP3411038B1 (enExample)
JP (1) JP6812449B2 (enExample)
KR (1) KR102749892B1 (enExample)
CN (1) CN108495632B (enExample)
AR (1) AR107494A1 (enExample)
AU (1) AU2017214243B2 (enExample)
BR (1) BR112018014712B1 (enExample)
CA (1) CA3011809C (enExample)
CO (1) CO2018007008A2 (enExample)
ES (1) ES2834608T3 (enExample)
IL (1) IL260665B (enExample)
MX (1) MX378363B (enExample)
MY (1) MY185367A (enExample)
RU (1) RU2733376C2 (enExample)
TW (1) TWI745345B (enExample)
WO (1) WO2017134051A1 (enExample)
ZA (1) ZA201805790B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109311858B (zh) 2016-05-26 2021-12-03 里科瑞尔姆Ip控股有限责任公司 Egfr抑制剂化合物
CN107556293B (zh) * 2017-09-19 2019-12-03 福建省微生物研究所 一种奥西替尼的合成工艺
WO2021111462A1 (en) * 2019-12-02 2021-06-10 Natco Pharma Limited An improved process for the preparation of osimertinib mesylate
US11780824B2 (en) * 2020-12-16 2023-10-10 Scinopharm Taiwan, Ltd. Process for preparing osimertinib or a salt thereof
KR20240055046A (ko) 2021-09-02 2024-04-26 신톤 비.브이. 오시머티닙을 제조하는 방법
WO2025124936A1 (en) 2023-12-15 2025-06-19 Synthon B.V. A process for making osimertinib

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4070401A (en) 1972-02-19 1978-01-24 Mitsui Toatsu Chemicals Inc. Method for the preparation of a halogenated aromatic amine
DK3686193T3 (da) * 2011-07-27 2022-05-30 Astrazeneca Ab 2-(2,4,5-substitueret anilino)pyrimidinforbindelser
CA2949793C (en) 2014-06-19 2024-02-27 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
CN104817541B (zh) * 2015-05-11 2017-06-16 苏州东南药业股份有限公司 一种抗肿瘤药物的合成方法

Also Published As

Publication number Publication date
AU2017214243A1 (en) 2018-09-06
MY185367A (en) 2021-05-11
MX378363B (es) 2025-03-10
WO2017134051A1 (en) 2017-08-10
RU2018130327A (ru) 2020-03-04
CN108495632A (zh) 2018-09-04
MX2018008966A (es) 2018-09-03
AR107494A1 (es) 2018-05-02
KR20180101610A (ko) 2018-09-12
CN108495632B (zh) 2021-12-31
EP3411038A1 (en) 2018-12-12
US11180477B2 (en) 2021-11-23
RU2018130327A3 (enExample) 2020-03-26
ZA201805790B (en) 2024-10-30
TWI745345B (zh) 2021-11-11
TW201736364A (zh) 2017-10-16
JP6812449B2 (ja) 2021-01-13
EP3411038B1 (en) 2020-09-09
RU2733376C2 (ru) 2020-10-01
JP2019508387A (ja) 2019-03-28
ES2834608T3 (es) 2021-06-18
BR112018014712A2 (pt) 2018-12-11
IL260665B (en) 2021-08-31
AU2017214243B2 (en) 2019-07-18
US20210122734A1 (en) 2021-04-29
CA3011809C (en) 2024-02-27
KR102749892B1 (ko) 2025-01-07
BR112018014712B1 (pt) 2023-10-31
CA3011809A1 (en) 2017-08-10

Similar Documents

Publication Publication Date Title
CO2022002637A2 (es) Proceso de fabricación de moduladores de cftr
CO2017001884A2 (es) Polimorfos de selinexor
MX2018014116A (es) Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil )pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirroli din-1-carboxamida y sales del mismo.
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
CO7141410A2 (es) Compuesto heterocíclico nitrogenado
CO2018007278A2 (es) Derivados de ácido aminobenzoico metaazacíclico como antagonistas de la integrina pan
MX2019012815A (es) Proceso para la preparacion de compuestos de 2,3-dihidrotiazolo[3, 2-a]pirimidin-4-io opticamente activo.
DOP2019000193A (es) Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende
BR112017023740A2 (pt) ?forma sólida de um composto, processo para a preparação de uma forma sólida, composição farmacêutica, método para o tratamento ou prevenção de doenças e utilização de uma forma sólida?
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
CU24488B1 (es) Nanopartículas terapéuticas que comprenden un ácido hidrófobo y un agente terapéutico útiles para diferentes tipos de cáncer y proceso de preparación de las mismas
BR112017006116A2 (pt) processos de preparação de compostos e compostos
MX375099B (es) Derivados de aminotiazol útiles como agentes antivíricos.
CO2017010806A2 (es) Método para manufacturar compuesto novedoso que contiene nitrógeno o sal del mismo e intermediario de manufacturación del compuesto novedoso que contiene nitrógeno o sal del mismo
UY36737A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
BR112019001980A2 (pt) inibidor de ido1 e método de preparação e aplicação do mesmo
MX2018008966A (es) Procesos mejorados para la preparacion de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo.
MX2019003026A (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
DOP2017000064A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
MX2025003091A (es) Metodo para producir derivado de heterociclideno acetamida
BR112017019850A2 (pt) ?processo melhorado para a preparação de apremilast?
MX2017006200A (es) Procesos e intermediarios para preparar dialcano eteres terminados con acido a, ?-dicarboxilico.
CO2022008127A2 (es) Procesos e intermediario para la preparación de oxetan-2-ilmetanamina
BR112018070345A2 (pt) processo para a preparação de derivados de 4-aminoindano e amidas de aminoindano relacionadas
MX2018007415A (es) Metodos para preparar 5,6-dihidro-6-fenilbenzo[f]isoquinolin-2-ami na sustituida.